ARTEL and IonGate Join Forces to Advance Drug Discovery Research in North America
News Jun 25, 2008
ARTEL and IonGate Biosciences announced their strategic partnership to support the growing application of IonGate’s drug discovery technology. The German biotechnology company will leverage ARTEL’s local infrastructure, customer relationships and market knowledge to increase the exposure and use of its discovery systems and assay development services in North America.
The partnership will focus on IonGate’s SURFE2R Technology, which enables effective research involving drug targets such as membrane transporters and ligand-gated ion channels.
Membrane transport proteins play an important role in numerous biological functions, and have been linked to cardiac, neurologic and metabolic disorders, yet they represent a relatively unexplored segment of the drug discovery market. The previous lack of technology for efficient transporter screening has led pharmaceutical companies to focus the majority of their research initiatives on other targets.
Ligand-gated ion channel proteins, while more frequently targeted, typically are also subject to less-than-optimal screening methods. IonGate’s SURFE2R (SURFace Electrogenic Event Reader) Technology represents a significant advance toward more efficient screening of transporters as well as ligand-gated ion channels.
“Transporter-focused drug discovery initiatives are poised for rapid growth worldwide, and the U.S. demand for our SURFE2R Technology is rising,” said Dr. Thiemo Gropp Ph.D., Managing Director, IonGate Biosciences GmbH. “With ARTEL’s support and market expertise, we will be able to deliver the same personalized support to our customers in North America as we deliver to our customers in Europe.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019